The efficacy and cost-effectiveness of various antiemetic regimens

Current Opinion in Oncology

Volumn 10, Issue 4, 1998, Pages 310-315

  Roila, Fausto ^a   Ballatori, Enzo ^b  

^a Policlinico Hospital   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUOROURACIL; METHOTREXATE; METOCLOPRAMIDE; SEROTONIN AGONIST;

ARTICLE; CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOMITING;

EID: 0031878676     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199807000-00006     Document Type: Article

References (51)

1. Kirchner V: Clinical studies to assess the economic impact of new therapies: pragmatic approaches to measuring costs. Anti-Cancer Drugs 1993, 4(suppl. 3):13-20.
2. Italian Group for Antiemetic Research; Ondansetron + dexamethasone versus metoclopramide + dexamethasone + diphenhydramine in the prevention of cisplatin-induced emesis. Lancet 1992, 340:96-99.
3. Cunningham D, Dicato M, Verweij J, Crombez R, de Mulder P, du Bois A, Stewart A, Smyth J, Selby P, van Straelen D, et al.: Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. Ann Oncol 1996, 7:277-282.
4. Italian Group for Antiemetic Research: Differences in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol 1993, 11:2396-2404.
5. Gralla RJ, Popovic W, Strupp J, Culleton V, Preston A, Friedman C: Can an oral antiemetic regimen be as effective as intravenous treatment against cisplatin; results of a 1054 patient randomized study of oral granisetron versus iv ondansetron [abstract]. Proc Am Soc Clin Oncol 1997, 16:52a. The first double-blind trial demonstrating similar antiemetic activity between oral and intravenous formulations of different 5-HT3 receptor antagonists in the prevention of cisplatin-induced acute emesis.
6. Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester EP, et al.: Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992, 10:1969-1975.
7. Seynaeve C, Schuller J, Buser K, Porteder H, Van Belle S, Sevelda P, Christmann D, Schmidt M, Kitchener H, Paes D, de Mulder PHM, on behalf of the Ondansetron Study Group: Comparison of the antiemetic efficacy of different doses of ondansetron given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis: a multicentre, double-blind, randomised, parallel group study. Br J Cancer 1992, 66:192-197.
8. Ruff P, Paska W, Goedhals L, Pouillart P, Rivière A, Vorobiof D, Bloch B. Jones A, Martin C, Brunet R, et al., on behalf of the Ondansetron and Granisetron Emesis Study Group: Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel group study. Oncology 1994, 51:113-118.
9. Italian Group for Antiemetic Research: Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis, Ann Oncol 1995, 6:805-810.
10. Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D: Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994, 12:2204-2210.
11. Riviere A, on behalf of the Granisetron Study Group: Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 1994, 69:967-971.
12. Soukop M, on behalf of the Granisetron Study Group: A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer 1994, 2:177-183.
13. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D, on behalf of the Granisetron Study Group: Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995, 13:1242-1248.
14. Van Belle SJP, Stamatakis L, Bleiberg H, Cocquyt VFJ, Michel J, de Bruijn KM: Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting. Ann Oncol 1994, 5:821-825.
15. Marty M, Kleisbauer J-P, Fournel P, Vergnenegre A, Carles P, Loria-Kanza Y, Simonetta C, de Bruijn KM, and the French Navoban Study Group: Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? Anti-Cancer Drugs 1995, 6:15-21.
16. Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W, for the Dolasetron Comparative Chemotherapy-induced Emesis Preventive Group: Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996, 14:2242-2249.
17. Thant M, Pendergrass K, Harman G, Modiano M, Martin L, Du Bois D, Cramer M, Hahne W: Double-blind, randomized study of the dose-response relationship across five single doses of iv dolasetron mesylate for the prevention of acute nausea and vomiting after cisplatin chemotherapy [abstract]. Proc Am Soc Clin Oncol 1996, 15:533.
18. Roila F, Ballatori E, Tonato M, Del Favero A: 5-HT3 receptor antagonists: differences and similarities. Eur J Cancer 1997, 33A:1364-1370. A review of the comparative studies among the 5-HT3 receptor antagonists showing their similar antiemetic activity and tolerability.
19. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S: Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989, 7:108-114.
20. The Italian Group for Antiemetic Research: Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 1997, 15:124-130. This double-blind study showed that oral ondansetron had antiemetic efficacy similar to that of metoclopramide when both were combined with dexamethasone in the prevention of cisplatin-induced delayed emesis. Ondansetron seems to be preferred in patients with acute emesis.
21. The Italian Group for Antiemetic Research: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995, 332:1-5.
22. The Italian Group for Antiemetic Research: Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. J Clin Oncol 1995, 13:2417-2426.
23. Kaiser L, Warr D, Hoskins P, Latreille J, Lofters W, Yau J, et al:. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994, 12:1050-1057.
24. Beck TM, York M, Chang A, Navari R, Harvey WH, Meshad M, Griffin D, Wentz A, for the S3A-376 Study Group: Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Cancer Invest 1997, 15:297-303. This large double-blind study confirms that two 8-mg oral doses of ondansetron yielded results similar to those of three oral 8-mg doses.
25. Dicato M: Oral treatment with ondansetron in an outpatient setting. Eur J Cancer 1991, 27(suppl 1):518-519.
26. Cubeddu LX, Pendergrass K, Ryan T, York M, Burton G, Meshad M, Galvin D, Ciociola AA, and the Ondansetron Study Group: Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Am J Clin Oncol 1994, 17:137-146.
27. Beck TM, Ciociola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chang A, Galvin D, Hart E, and the Ondansetron Study Group: Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 1993, 118:407-413.
28. Bleiberg HH, Spielmann M, Falkson G, Romain D: Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study. Clin Ther 1995, 17:38-51.
29. Ettinger DS, Eisenberg PD, Fitts D, Wilson-Lynch K, Yocom K: A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer 1996, 78:144-151.
30. Rubenstein EB, Gralla RJ, Hainsworth JD, Hesketh PJ, Grote TH, Modiano MR, et al.: Randomized, double-blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Cancer 1997, 79:1216-1224. This double-blind study shows similar efficacy between a 100-and 200-mg oral dose of dolasetron.
31. Fauser AA, Duclos B, Chemaissani A, Del Favero A, Cognetti F, Diaz Rubio E, et al.: Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer 1996, 32A:1523-1529.
32. Grote TH, Pineda LF, Figlin RA, Pendergrass KB, Hesketh PJ, Karlan BY, Reeves JA, Porter LL, Benedict CR, Hahne W, on behalf of the Oral Dolasetron Dose Response Study Group: Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Cancer J Sci Am 1997, 3:45-51. This study shows a 200-mg single oral dose of dolasetron as optimal in the prevention of emesis induced by moderately emetogenic chemotherapy.
33. The Italian Group for Antiemetic Research: Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? Ann Oncol 1997, 8:561-567. This observational study documents the incidence and the prognostic factors of delayed emesis in patients undergoing three consecutive courses of moderately emetogenic chemotherapy.
34. Koo WH, Ang PT: Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 1996, 7:71-74.
35. Pater JL, Lofters WS, Zee B, Dempsey E, Walde D, Moquin J-P, et al.: The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 1997, 8:181-185. This double-blind study shows that the addition of a 5-HT3 receptor antagonist to dexamethasone slightly improved the complete control rate of delayed emesis in patients undergoing moderately emetogenic chemotherapy.
36. Rath U, Upadhyaya BK, Arechavala E, Bockmann H, Dearnaley D, Droz JP, et al.: Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology 1993, 50:168-172.
37. Nicolai N, Mangiarotti B, Salvioni R, Piva L, Faustini M, Pizzocaro G: Dexamethasone plus ondansetron versus dexamethasone plus alizapride in the prevention of emesis induced by cisplatin-containing chemotherapies for urological cancers. Eur Urol 1993, 23:450-456.
38. Fox SM, Einhorn LH, Cox E, Powell N, Abdy A: Ondansetron vs ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 1993, 11:2391-2395.
39. Levitt M, Warr D, Yelle L, Rayner HL, Lofters WS, Perrault DJ, et al.: Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate and fluorouracil. N Engl J Med 1993, 328:1081-1084.
40. O'Brien BJ, Rusthoven J, Rocchi A, Latreille J, Fine S, Vandenberg T, Laberge F: Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres, Can Med Assoc J 1993, 149:296-300.
41. Jones AL, Lee GJ, Bosanquet N: The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis. Eur J Cancer 1993, 29A:51-56.
42. Buxton MJ, O'Brien BJ: Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting. Br J Cancer 1992, 66(suppl 19):64-67.
43. Cunningham D, Gore M, Davidson N, Miocevich M, Manchanda M, Wells N: The real costs of emesis: an economic analysis of ondansetron vs metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur J Cancer 1993, 29A:303-306.
44. Tanneberger ST, Lelli G, Martoni A, Piana E, Pannuti F: The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach of health technology assessment (real-cost-benefit index) J Chemother 1992, 4:326-331.
45. Sands R, Roberts JT, Marsh M, Gill A: Low dose ondansetron and dexamethasone: a cost effective alternative to high dose metoclopramide/dexamethasone/lorazepam in the prevention of acute cisplatin induced emesis. Clin Oncol 1992, 4:67-68.
46. Ballatori E, Roila F, Berto P, De Angelis V, Neri C, Olivieri A, Tonato M, Del Favero A: Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy. Pharmacoeconomics 1994, 5:227-237.
47. Zbrozek AS, Cantor SB, Cardenas MP, Hill DP: Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm 1994, 51:1555-1563.
48. Rubenstein EB, Elting LS: Pharmacoeconomic analyses: whose perspective counts and costs the most? Am J Hosp Pharm 1994, 51:1564-1569.
49. Grunberg SM, Boutin N, Ireland A, Miner S, Silveira J, Ashikaga T: Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer 1996, 4:435-439.
50. Cox F, Hirsch J: Ondansetron: a cost-effective advance in anti-emetic therapy. Oncology 1993, 50:186-190.
51. Kirchner V, Aapro M, Alberto P, Terrey J-P: The cost effectiveness of granisetron compared to metoclopramide with dexamethasone [abstract], Proc Am Soc Clin Oncol 1992, 11:379.